GEN Exclusives

More »

GEN News Highlights

More »
Sep 21, 2006

Cardinal Health Inks Cell Line Development Deal with Wyeth

  • Cardinal Health entered a feasibility agreement with Wyeth to develop cell lines using Cardinal Health’s Gene Product Expression (GPEx®) cell line engineering technology.

    Cardinal Health will use the technology to engineer cell lines that express two undisclosed biopharmaceutical molecules in experiments that will determine if the GPEx approach is a feasible augmentation to Wyeth’s current production methods.

    In addition to enabling rapid cell line development and availability of candidate gene products, the GPEx technology is “well suited for both efficient pilot and large-scale production of antibodies and other therapeutic recombinant proteins,” notes Paul Weiss, Ph.D., president of Cardinal Health’s biopharmaceutical development services center.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?